Nintedanib, marketed under the brand names Ofev and Vargatef, is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer.
Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR).
It was developed by Boehringer Ingelheim. At an assumed cost of 39,300 pounds per year it does not appear to be cost effective for IPF in the United Kingdom.

Chemical Name	Nintedanib
Synonyms	Ofev;Imidafenacin;(Z)-N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-(((2-oxoindolin-3-ylidene)(phenyl)methyl)amino)phenyl)acetamide;Intedanib;Vargatef;Staybla;methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate;Uritos;Collapse
CAS No.	656247-17-5
Molecular Formula	C31H33N5O4
Molecular Weight	539.62500
PSA	94.22000
LogP	3.70270